Lamivudine (3TC) phosphorylation and drug interactions in vitro

Biochemical Pharmacology

Volumn 54, Issue 5, 1997, Pages 589-595

  Kewn, Stephen ^a   Veal, Gareth J ^a   Hoggard, Patrick G ^a   Barry, Michael G ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

3TC; Combination therapy; Drug interactions; In vitro; Nucleoside analogues; Phosphorylation

Indexed keywords

DEOXYCYTIDINE; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CELLS, CULTURED; DEOXYCYTIDINE; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; HUMANS; KINETICS; LAMIVUDINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MITOGENS; MODELS, CHEMICAL; MONOCYTES; PHOSPHORYLATION; STAVUDINE; TUMOR CELLS, CULTURED; ZALCITABINE; ZIDOVUDINE;

EID: 0030776777     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00189-5     Document Type: Article

References (36)

1. Coates JAV, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC and Cameron JM, (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 36: 733-739, 1992.
2. Pluda JM, Cooley TP, Montaner JSG, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, Hirst HM, Vicary CA, Quinn JB, Yuen GJ, Wainberg MA, Rubin M and Yarchoan R, A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 171: 1438-1447, 1995.
3. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster P and Markham PD, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500-503, 1984.
4. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H and Barry DW, Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transciptase. Proc Natl Acad Sci USA 83: 8333-8337, 1986.
5. Mitsuya H and Broder S, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Nad Acad Sci USA 83: 1911-1915, 1986.
6. St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ and Furman PA, 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31: 1972-1977, 1987.
7. Bridges EG, Dutschman GE, Gullen EA and Cheng Y-C, Favourable interaction of β-L (-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 51: 731-736, 1996.
8. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA and Cameron JM, High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37: 2231-2234, 1993.
9. Delta Coordinating Committee, Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283-291, 1996.
10. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS and Merigan TC, for the AIDS clinical trials group study 175 study team, A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 335: 1081-1090, 1996.
11. Tisdale M, Kemp SD, Parry NR and Larder BA, Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90: 5653-5656, 1993.
12. Larder BA, Kemp SD and Harrigan R, Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699, 1995.
13. Hoggard PG, Veal GJ, Wild MJ, Barry MG and Back DJ, Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 39: 1376-1378, 1995.
14. Hoggard PG, Kewn S, Barry MG, Khoo SH and Back DJ, Drug interactions with d4T phosphorylation in vitro. Antimicrob Agents Chemother 41: 1231-1236, 1997.
15. Veal GJ, Wild MJ, Barry MG and Back DJ, Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol 38: 323-328, 1994.
16. Veal GJ, Barry MG and Back DJ, Zalcitabine (ddC) phosphorylation and drug interactions. Antiviral Chem Chemother 6: 379-384, 1995.
17. Veal GJ, Hoggard PG, Barry MG, Khoo S and Back DJ, Interaction between 3TC (lamivudine) and other nucleoside analogues for intracellular phosphorylation. AIDS 10: 546-548, 1996.
18. Gao W-Y, Shirasaka T, Johns DG, Broder S and Mitsuya H, Differential phosphorylation of azidothymidine, dideoxycytidine and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 91: 2326-2333, 1993.
19. Moore KHP, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK and Hussey EK, Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 59: 550-558, 1996.
20. Chang C-N, Skalski V, Zhou JH and Cheng Y-C, Biochemical pharmacology of (+)-and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitus B virus agents. J Biol Chem 267: 22414-22420, 1992.
21. Gao W-Y, Agbaria R, Driscoll JS and Mitsuya H, Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3,-dideoxynucleoside analogues in resting and activated human cells. J Biol Chem 269: 12633-12638, 1994.
22. Gray NM, Marr CLP, Penn CR, Cameron JM and Bethell RC, The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmocol 50: 1043-1051, 1995.
23. Cammack N, Rouse P, Marr CLP, Reid PJ, Boehme RE, Coates JAV, Penn CR and Cameron JM, Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 43: 2059-2064, 1992.
24. Blum RM, Liao SHT, Good SS and De Miranda P, Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 85: 189-194, 1988.
25. Klecker RWJ, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S and Myers CE, Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 28: 837-842, 1988.
26. Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA and Barbhaiya RH, Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 49: 523-535, 1991.
27. Browne MJ, Mayer KH, Chafee SBD, Dudley MN, Posner MR, Steinberg SM, Graham KK, Geletko SM, Zinner SH, Denamn SL, Dunkle LM, Kaul S, McLaren C, Skowron G, Kouttab NM, Kennedy TA, Weitberg AB and Curt GA, 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patietns with AIDS or AIDS-related complex: A phase I trial. J Infect Dis 167: 21-29, 1993.
28. Balzarini J, Pauwels R, Baba M, Herdewijn P, De Clercq E, Broder S and Johns DG, The in vitro and in vivo anti-retrovirus activity and intracellular metabolism of 3′-azido2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on cell species. Biochem Pharmacol 37: 897-903, 1988.
29. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Pinedo HM and Peters GJ, Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 51: 911-918, 1996.
30. Shewach DS, Liotta DC and Schinazi RF, Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem Pharmacol 45: 1540-1543, 1993.
31. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B and Griffin JL, Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322: 1098-1105, 1990.
32. Modica-Napolitano JS, AZT causes tissue specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 194: 170-177, 1993.
33. Frick LW, Nelson DJ, St Clair MH, Furman PA and Krenitsky TA, Effects of 3′azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun 154: 124-129, 1988.
34. Ho H-T and Hitchcock MJM, Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 33: 844-849, 1989.
35. Hitchcock MJM, 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), an anti-HIV agent. Antiviral Chem Chemother 2: 125-132, 1991.
36. Nave J-F, Eschbach A, Wolf-Kugel D, Halazy S and Balzarini J, Enzymatic phosphorylation and pyrophosphorylation of 2′,3′-dideoxyadenosine-5′-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2′,3′-dideoxyinosine. Biochem Pharmacol 48: 1105-1112, 1994.